Thelansis’s "HER2-Positive Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HER2-Positive Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
HER2-positive gastric cancer is a distinct molecular subtype of gastric and gastroesophageal junction adenocarcinoma characterized by the overexpression or amplification of the Human Epidermal Growth Factor Receptor 2 (HER2). Found in approximately 10–20% of cases—most frequently in the intestinal histological subtype—HER2 act as a potent driver of tumor cell proliferation and survival. Diagnostic confirmation is mandatory via immunohistochemistry (IHC) and, when necessary, fluorescence in situ hybridization (FISH), following gastric-specific scoring criteria that account for tumor heterogeneity. The identification of HER2 positivity serves as a critical predictive biomarker for the initiation of targeted therapy. The current standard of care for advanced disease involves combining platinum-based chemotherapy with Trastuzumab, a monoclonal antibody that blocks HER2 signaling, which has been shown to significantly extend overall survival. Furthermore, emerging therapies such as Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, now provide powerful second-line options for patients who progress on initial HER2-targeted regimens.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest HER2-Positive Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the HER2-Positive Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.